Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: A prognostic value ?

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 2, 2011, Pages 237-245

  Martelli, N ^a   Mathieu, O ^a   Margueritte, G ^b   Bozonnat, M C ^c   Dauras J P ^c   Bressolle, F ^d   Hillaire Buys, D ^a   Peyriere H ^a  

^a LAPEYRONIE HOSPITAL   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d UNIV MONTPELLIER   (France)

Author keywords

acute lymphobastic leukemia; children; methotrexate; pharmacokinetics; relapse

Indexed keywords

CYTARABINE; FOLINIC ACID; METHOTREXATE; PREDNISOLONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; COHORT ANALYSIS; COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MEGADOSE; EARLY DIAGNOSIS; EVENT FREE SURVIVAL; FEMALE; HEMATOLOGIC DISEASE; HUMAN; KIDNEY FAILURE; LEUKEMIA RELAPSE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUROTOXICITY; OUTCOME ASSESSMENT; PROGNOSIS; RELIABILITY; SIDE EFFECT; SYSTEMIC DISEASE;

ADOLESCENT; AGE FACTORS; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; MALE; METHOTREXATE; MODELS, BIOLOGICAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; TIME FACTORS;

EID: 79952270172     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01179.x     Document Type: Article

References (24)

1. Linabery AM, Ross JA, (2008) Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer, 112, 416-432.
2. Goubin A, Auclerc MF, Auvrignon A, et al. (2006) Survival in France after childhood acute leukaemia and non-Hodgkin's lymphoma (1990-2000). European Journal of Cancer, 42, 534-541. (Pubitemid 43227934)
3. Sterba J, Valik D, Bajciova V, et al. (2005) High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how? Neoplasma, 52, 456-463. (Pubitemid 41809402)
4. Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR, (1979) Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemotherapy and Pharmacology, 3, 161-166. (Pubitemid 10203329)
5. Evans WE, Abromowitch M, Crom WR, et al. (1987) Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia. NCI Monographs, 5, 81-85. (Pubitemid 18000401)
6. Borsi JD, Moe PJ, (1987) Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. Cancer, 60, 3020-3024. (Pubitemid 18005878)
7. Seidel H, Nygaard R, Moe PJ, et al. (1997) On the prognostic value of systemic methotrexate clearance in childhood acute lymphocytic leukemia. Leukemia Research, 21, 429-434. (Pubitemid 27308238)
8. Evans WE, Relling MV, Rodman JH, et al. (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. The New England Journal of Medicine, 338, 499-505. (Pubitemid 28103133)
9. Vilmer E, Suciu S, Ferster A, et al. (2000) Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia, 14, 2257-2266. (Pubitemid 32042266)
10. Du Bois D, Du Bois EF, (1989) A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition, 5, 303-311.
11. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A, (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics, 58, 259-263.
12. Cockcroft DW, Gault MH, (1976) Prediction of creatinine clearance from serum creatinine. Nephron, 16, 31-41.
13. Piard C, Bressolle F, Fakhoury M, et al. (2007) A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology, 60, 609-620. (Pubitemid 47084260)
14. Odoul F, Le Guellec C, Lamagnere JP, et al. (1999) Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. Fundamental and Clinical Pharmacologyundam, 13, 595-604.
15. Donelli MG, Zucchetti M, Robatto A, et al. (1995) Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. Medical and Pediatric Oncology, 24, 154-159.
16. Wolfrom C, Hepp R, Hartmann R, Breithaupt H, Henze G, (1990) Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. European Journal of Clinical Pharmacology, 39, 377-383. (Pubitemid 20362350)
17. Clavel J, Goubin A, Auclerc MF, et al. (2004) Incidence of childhood leukaemia and non-Hodgkin's lymphoma in France: National Registry of Childhood Leukaemia and Lymphoma, 1990-1999. European Journal of Cancer Prevention, 13, 97-103. (Pubitemid 38585328)
18. Pui CH, Evans WE, (2006) Treatment of acute lymphoblastic leukemia. The New England Journal of Medicine, 354, 166-178. (Pubitemid 43076714)
19. Pui CH, Boyett JM, Relling MV, et al. (1999) Sex differences in prognosis for children with acute lymphoblastic leukemia. Journal of Clinical Oncology, 17, 818-824. (Pubitemid 29109311)
20. Ansari M, Krajinovic M, (2007) Pharmacogenomics of acute leukemia. Pharmacogenomics, 8, 817-834. (Pubitemid 47296598)
21. Ge Y, Haska CL, LaFiura K, et al. (2007) Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Clinical Cancer Research, 13, 451-457. (Pubitemid 46225349)
22. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M, (2002) Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood, 100, 3832-3834. (Pubitemid 35303961)
23. Costea I, Moghrabi A, Laverdiere C, Graziani A, Krajinovic M, (2006) Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica, 91, 1113-1116. (Pubitemid 44204780)
24. Peyriere H, Poiree M, Cociglio M, et al. (2001) Reversal of neurologic disturbances related to high-dose methotrexate by aminophylline. Medical and Pediatric Oncology, 36, 662-664. (Pubitemid 32402168)